Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations

Amy Lightner, N. P. McKenna, C. S. Tse, Laura E. H. Raffals, Edward Vincent Loftus, Jr, K. L. Mathis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. Aim: We sought to compare 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy. Methods: A retrospective review of all Crohn's disease patients who received vedolizumab within 12 weeks of a major abdominal or pelvic operation was performed. Two control cohorts consisted of Crohn's disease patients treated with TNFα inhibitors or no biologic therapy. Results: One hundred Crohn's disease patients received vedolizumab within 12 weeks of an abdominal operation. Vedolizumab-treated patients underwent an equivalent rate of laparoscopic surgery (P =.25), had fewer anastomoses performed (P =.0002), and had equally frequent diversion in the setting of anastomoses (P =.47). Thirty-two vedolizumab-treated patients experienced postoperative infectious complications (32%), 26 of which were surgical site infections (26%). The vedolizumab-treated group experienced no difference in nonsurgical site infections (6% vs 5% anti-TNFα and 2% nonbiologic; P =.34), but significantly higher rates of surgical site infections (26% vs 8% and 11%; P <.001). On univariate and multivariate analysis, exposure to vedolizumab remained a significant predictor of postoperative surgical site infection (P <.001 and P =.002). Conclusions: Twenty-six per cent of Crohn's disease patients who received vedolizumab within 12 weeks prior to a major abdominal operation experienced a 30-day postoperative surgical site infection, significantly higher than that of patients receiving TNFα inhibitors or no biologic therapy. Vedolizumab within 12 weeks of surgery remained a predictor of 30-day postoperative surgical site infection on multivariable analysis. While vedolizumab-treated Crohn's disease patients may be a sicker cohort of patients, it is important to consider these findings with regard to preoperative counselling, operative timing and primary closure of wounds.

Original languageEnglish (US)
Pages (from-to)573-580
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume47
Issue number5
DOIs
StatePublished - Mar 1 2018

Fingerprint

Crohn Disease
Surgical Wound Infection
Biological Therapy
vedolizumab
Laparoscopy
Counseling
Multivariate Analysis
Wounds and Injuries

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. / Lightner, Amy; McKenna, N. P.; Tse, C. S.; Raffals, Laura E. H.; Loftus, Jr, Edward Vincent; Mathis, K. L.

In: Alimentary Pharmacology and Therapeutics, Vol. 47, No. 5, 01.03.2018, p. 573-580.

Research output: Contribution to journalArticle

@article{cb33fca3f0f7465e985d7659942c1b1e,
title = "Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations",
abstract = "Background: Up to 80{\%} of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. Aim: We sought to compare 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy. Methods: A retrospective review of all Crohn's disease patients who received vedolizumab within 12 weeks of a major abdominal or pelvic operation was performed. Two control cohorts consisted of Crohn's disease patients treated with TNFα inhibitors or no biologic therapy. Results: One hundred Crohn's disease patients received vedolizumab within 12 weeks of an abdominal operation. Vedolizumab-treated patients underwent an equivalent rate of laparoscopic surgery (P =.25), had fewer anastomoses performed (P =.0002), and had equally frequent diversion in the setting of anastomoses (P =.47). Thirty-two vedolizumab-treated patients experienced postoperative infectious complications (32{\%}), 26 of which were surgical site infections (26{\%}). The vedolizumab-treated group experienced no difference in nonsurgical site infections (6{\%} vs 5{\%} anti-TNFα and 2{\%} nonbiologic; P =.34), but significantly higher rates of surgical site infections (26{\%} vs 8{\%} and 11{\%}; P <.001). On univariate and multivariate analysis, exposure to vedolizumab remained a significant predictor of postoperative surgical site infection (P <.001 and P =.002). Conclusions: Twenty-six per cent of Crohn's disease patients who received vedolizumab within 12 weeks prior to a major abdominal operation experienced a 30-day postoperative surgical site infection, significantly higher than that of patients receiving TNFα inhibitors or no biologic therapy. Vedolizumab within 12 weeks of surgery remained a predictor of 30-day postoperative surgical site infection on multivariable analysis. While vedolizumab-treated Crohn's disease patients may be a sicker cohort of patients, it is important to consider these findings with regard to preoperative counselling, operative timing and primary closure of wounds.",
author = "Amy Lightner and McKenna, {N. P.} and Tse, {C. S.} and Raffals, {Laura E. H.} and {Loftus, Jr}, {Edward Vincent} and Mathis, {K. L.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/apt.14459",
language = "English (US)",
volume = "47",
pages = "573--580",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations

AU - Lightner, Amy

AU - McKenna, N. P.

AU - Tse, C. S.

AU - Raffals, Laura E. H.

AU - Loftus, Jr, Edward Vincent

AU - Mathis, K. L.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background: Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. Aim: We sought to compare 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy. Methods: A retrospective review of all Crohn's disease patients who received vedolizumab within 12 weeks of a major abdominal or pelvic operation was performed. Two control cohorts consisted of Crohn's disease patients treated with TNFα inhibitors or no biologic therapy. Results: One hundred Crohn's disease patients received vedolizumab within 12 weeks of an abdominal operation. Vedolizumab-treated patients underwent an equivalent rate of laparoscopic surgery (P =.25), had fewer anastomoses performed (P =.0002), and had equally frequent diversion in the setting of anastomoses (P =.47). Thirty-two vedolizumab-treated patients experienced postoperative infectious complications (32%), 26 of which were surgical site infections (26%). The vedolizumab-treated group experienced no difference in nonsurgical site infections (6% vs 5% anti-TNFα and 2% nonbiologic; P =.34), but significantly higher rates of surgical site infections (26% vs 8% and 11%; P <.001). On univariate and multivariate analysis, exposure to vedolizumab remained a significant predictor of postoperative surgical site infection (P <.001 and P =.002). Conclusions: Twenty-six per cent of Crohn's disease patients who received vedolizumab within 12 weeks prior to a major abdominal operation experienced a 30-day postoperative surgical site infection, significantly higher than that of patients receiving TNFα inhibitors or no biologic therapy. Vedolizumab within 12 weeks of surgery remained a predictor of 30-day postoperative surgical site infection on multivariable analysis. While vedolizumab-treated Crohn's disease patients may be a sicker cohort of patients, it is important to consider these findings with regard to preoperative counselling, operative timing and primary closure of wounds.

AB - Background: Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. Aim: We sought to compare 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy. Methods: A retrospective review of all Crohn's disease patients who received vedolizumab within 12 weeks of a major abdominal or pelvic operation was performed. Two control cohorts consisted of Crohn's disease patients treated with TNFα inhibitors or no biologic therapy. Results: One hundred Crohn's disease patients received vedolizumab within 12 weeks of an abdominal operation. Vedolizumab-treated patients underwent an equivalent rate of laparoscopic surgery (P =.25), had fewer anastomoses performed (P =.0002), and had equally frequent diversion in the setting of anastomoses (P =.47). Thirty-two vedolizumab-treated patients experienced postoperative infectious complications (32%), 26 of which were surgical site infections (26%). The vedolizumab-treated group experienced no difference in nonsurgical site infections (6% vs 5% anti-TNFα and 2% nonbiologic; P =.34), but significantly higher rates of surgical site infections (26% vs 8% and 11%; P <.001). On univariate and multivariate analysis, exposure to vedolizumab remained a significant predictor of postoperative surgical site infection (P <.001 and P =.002). Conclusions: Twenty-six per cent of Crohn's disease patients who received vedolizumab within 12 weeks prior to a major abdominal operation experienced a 30-day postoperative surgical site infection, significantly higher than that of patients receiving TNFα inhibitors or no biologic therapy. Vedolizumab within 12 weeks of surgery remained a predictor of 30-day postoperative surgical site infection on multivariable analysis. While vedolizumab-treated Crohn's disease patients may be a sicker cohort of patients, it is important to consider these findings with regard to preoperative counselling, operative timing and primary closure of wounds.

UR - http://www.scopus.com/inward/record.url?scp=85038093740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038093740&partnerID=8YFLogxK

U2 - 10.1111/apt.14459

DO - 10.1111/apt.14459

M3 - Article

C2 - 29250800

AN - SCOPUS:85038093740

VL - 47

SP - 573

EP - 580

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -